JO
ITOS

John Overdeck’s iTeos Therapeutics ITOS Stock Holding History

John Overdeck’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-122,697
Closed -$1.25M – 3345
2024
Q3 		$1.25M Buy
122,697
+35,077
+40% +$535K ﹤0.01% 1984
2024
Q2 		$1.3M Buy
87,620
+7,568
+9% +$108K ﹤0.01% 1841
2024
Q1 		$1.09M Buy
80,052
+52,835
+194% +$576K ﹤0.01% 1904
2023
Q4 		$298K Buy
+27,217
New +$270K ﹤0.01% 2700
2022
Q3 		– Sell
-25,600
Closed -$527K – 2633
2022
Q2 		$527K Sell
25,600
-199,008
-89% -$4.72M ﹤0.01% 1801
2022
Q1 		$7.23M Buy
224,608
+17,225
+8% +$626K 0.02% 747
2021
Q4 		$9.66M Buy
207,383
+39,613
+24% +$1.32M 0.02% 803
2021
Q3 		$4.53M Buy
167,770
+66,646
+66% +$1.74M 0.01% 1302
2021
Q2 		$2.59M Buy
+101,124
New +$2.41M 0.01% 1666

Other funds holding ITOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

John Overdeck's ITOS Position: Q4 2024 in Review

John Overdeck sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 122,697 shares — an estimated $1.25M sold.

John Overdeck first reported a position in ITOS in Q2 2021 and held it in 9 quarters. The position peaked at $9.66M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

  • John Overdeck reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
  • John Overdeck sold 122,697 iTeos Therapeutics shares in Q4 2024, an estimated $1.25M.
  • John Overdeck first reported a position in iTeos Therapeutics in Q2 2021 and held it in 9 quarters.
  • John Overdeck's iTeos Therapeutics position peaked at $9.66M in Q4 2021.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.